Exhibit 99.2 CONFERENCE CALL & WEBCAST: ORAL PACLITAXEL AND ENCEQUIDAR September 8, 2020 NASDAQ:ATNX www.athenex.comExhibit 99.2 CONFERENCE CALL & WEBCAST: ORAL PACLITAXEL AND ENCEQUIDAR September 8, 2020 NASDAQ:ATNX www.athenex.com
Forward Looking Statements Except for historical information, all of the statements, expectations, and assumptions contained in this presentation constitute forward- looking statements. These statements include descriptions regarding the intent, belief or current expectations of Athenex, Inc. (the “Company”), its officers or its management with respect to the consolidated results of operations and financial condition of the Company. These statements can be recognized by the use of words such as “anticipate,” “believe,” “consider,” “continue,” “could,” “estimate,” “expect,” “explore,” “foresee,” “guidance,” “intend,” “likely,” “may,” “opportunity,” “plan,” “potential,” “predict,” “preliminary,” “probable,” “project,” “promising,” “seek,” “should,” “will,” or words of similar expressions. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties. Actual results might differ materially from those explicit or implicit in the forward-looking statements. Important factors that could cause actual results to differ materially include: the development stage of our primary clinical candidates and related risks involved in drug development, clinical trials, regulation, manufacturing and commercialization; our ability to obtain and maintain regulatory approvals for our product candidates; our reliance on third parties for success in certain areas of Athenex’s business; our history of operating losses and need to raise additional capital to continue as a going concern; our ability to service our existing and any future debt obligations and comply with financial and restrictive covenants contained in the agreements governing our indebtedness; risks and uncertainties related to the COVID-19 pandemic and its potential impact on our operations, cash flow and financial condition; our ability to integrate acquired assets and businesses into our existing operations; competition; intellectual property risks; risks relating to doing business internationally and in China; the risk of production slowdowns or stoppages or other interruptions at our Chongqing facilities; and the other risk factors set forth from time to time in the Company’s public filings with the U.S. Securities and Exchange Commission (the “SEC”), copies of which are available for free in the Investor Relations section of the Company’s website at https://ir.athenex.com/financial-information/sec-filings or upon request from the Company’s Investor Relations Department. Information about the Company and any forward-looking statements contained in this presentation are provided and made only as of 8 September 2020 and should not be relied upon as predictions of future events. The Company assumes no obligation and does not undertake to revise or update forward-looking statements to reflect future events or circumstances, except as required by law. DISCLAIMER This presentation does not constitute or form part of any offer for sale or subscription of or solicitation or invitation of any offer to buy or subscribe for any securities. Neither this presentation nor any part of it shall form the basis of or be relied upon in connection with any contract or commitment whatsoever. Specifically, this presentation does not constitute a “prospectus” within the meaning of the Securities Act of 1933, as amended. Our historical results are not necessarily indicative of results to be expected for any future period. The financial data contained in this presentation for the periods and as of the dates indicated are qualified by reference to and should be read in conjunction with our financial statements and related notes and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included in our public filings with the SEC. 2 September 2020Forward Looking Statements Except for historical information, all of the statements, expectations, and assumptions contained in this presentation constitute forward- looking statements. These statements include descriptions regarding the intent, belief or current expectations of Athenex, Inc. (the “Company”), its officers or its management with respect to the consolidated results of operations and financial condition of the Company. These statements can be recognized by the use of words such as “anticipate,” “believe,” “consider,” “continue,” “could,” “estimate,” “expect,” “explore,” “foresee,” “guidance,” “intend,” “likely,” “may,” “opportunity,” “plan,” “potential,” “predict,” “preliminary,” “probable,” “project,” “promising,” “seek,” “should,” “will,” or words of similar expressions. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties. Actual results might differ materially from those explicit or implicit in the forward-looking statements. Important factors that could cause actual results to differ materially include: the development stage of our primary clinical candidates and related risks involved in drug development, clinical trials, regulation, manufacturing and commercialization; our ability to obtain and maintain regulatory approvals for our product candidates; our reliance on third parties for success in certain areas of Athenex’s business; our history of operating losses and need to raise additional capital to continue as a going concern; our ability to service our existing and any future debt obligations and comply with financial and restrictive covenants contained in the agreements governing our indebtedness; risks and uncertainties related to the COVID-19 pandemic and its potential impact on our operations, cash flow and financial condition; our ability to integrate acquired assets and businesses into our existing operations; competition; intellectual property risks; risks relating to doing business internationally and in China; the risk of production slowdowns or stoppages or other interruptions at our Chongqing facilities; and the other risk factors set forth from time to time in the Company’s public filings with the U.S. Securities and Exchange Commission (the “SEC”), copies of which are available for free in the Investor Relations section of the Company’s website at https://ir.athenex.com/financial-information/sec-filings or upon request from the Company’s Investor Relations Department. Information about the Company and any forward-looking statements contained in this presentation are provided and made only as of 8 September 2020 and should not be relied upon as predictions of future events. The Company assumes no obligation and does not undertake to revise or update forward-looking statements to reflect future events or circumstances, except as required by law. DISCLAIMER This presentation does not constitute or form part of any offer for sale or subscription of or solicitation or invitation of any offer to buy or subscribe for any securities. Neither this presentation nor any part of it shall form the basis of or be relied upon in connection with any contract or commitment whatsoever. Specifically, this presentation does not constitute a “prospectus” within the meaning of the Securities Act of 1933, as amended. Our historical results are not necessarily indicative of results to be expected for any future period. The financial data contained in this presentation for the periods and as of the dates indicated are qualified by reference to and should be read in conjunction with our financial statements and related notes and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included in our public filings with the SEC. 2 September 2020
Agenda and Introduction INTRODUCTION Johnson Lau, Chief Executive Officer ORAL PACLITAXEL: DEVELOPMENT UPDATE • NDA Filing for Metastatic Breast Cancer • Initiation of Oral Paclitaxel in the I-SPY 2 Trial Rudolf Kwan, Chief Medical Officer ORAL PACLITAXEL: COMMERCIAL STRATEGY Timothy Cook, SVP, Global Commercial Oncology ORAL PACLITAXEL: LABEL EXPANSION STRATEGIES Rudolf Kwan, Chief Medical Officer Timothy Cook, SVP, Global Commercial Oncology KEY TAKEAWAYS Johnson Lau, Chief Executive Officer Q&A 3 September 2020Agenda and Introduction INTRODUCTION Johnson Lau, Chief Executive Officer ORAL PACLITAXEL: DEVELOPMENT UPDATE • NDA Filing for Metastatic Breast Cancer • Initiation of Oral Paclitaxel in the I-SPY 2 Trial Rudolf Kwan, Chief Medical Officer ORAL PACLITAXEL: COMMERCIAL STRATEGY Timothy Cook, SVP, Global Commercial Oncology ORAL PACLITAXEL: LABEL EXPANSION STRATEGIES Rudolf Kwan, Chief Medical Officer Timothy Cook, SVP, Global Commercial Oncology KEY TAKEAWAYS Johnson Lau, Chief Executive Officer Q&A 3 September 2020
Increasing Importance of Oral Chemotherapy Options • Consideration of alternative dosing schedule to allow for fewer in-person visits to the cancer center and/or the infusion center • Switch from infusional therapy to oral oncolytics if equivalent formulation is available 4 Source: https://www.nccn.org/about/news/newsinfo.aspx?NewsID=2025 https://www.fda.gov/news-events/press-announcements/fda-approves-new-therapy-myelodysplastic-syndromes-mds-can-be-taken-home September 2020Increasing Importance of Oral Chemotherapy Options • Consideration of alternative dosing schedule to allow for fewer in-person visits to the cancer center and/or the infusion center • Switch from infusional therapy to oral oncolytics if equivalent formulation is available 4 Source: https://www.nccn.org/about/news/newsinfo.aspx?NewsID=2025 https://www.fda.gov/news-events/press-announcements/fda-approves-new-therapy-myelodysplastic-syndromes-mds-can-be-taken-home September 2020
D E V E L O P M E N T U P D A T E : O r a l P a c l i t a x e l N D A f o r M e t a s t a t i c B r e a s t C a n c e rD E V E L O P M E N T U P D A T E : O r a l P a c l i t a x e l N D A f o r M e t a s t a t i c B r e a s t C a n c e r
Oral Paclitaxel and Encequidar Regulatory Update • NDA of Oral Paclitaxel for metastatic breast cancer accepted for filing by the U.S. FDA • Priority Review granted • U.S. FDA grants Priority Review to applications for potential therapies that, if approved, would be significant improvements in the safety or effectiveness of the treatment, diagnosis, or 1 prevention of serious conditions when compared to standard applications • PDUFA target action date of February 28, 2021 • FDA indicated it is currently not planning to hold an advisory committee meeting • NDA submission based on data from Phase III pivotal study – a randomized, controlled clinical trial designed to compare the safety and efficacy of Oral Paclitaxel monotherapy versus IV Paclitaxel monotherapy for the treatment of metastatic breast cancer 6 1 Source: https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/priority-review September 2020Oral Paclitaxel and Encequidar Regulatory Update • NDA of Oral Paclitaxel for metastatic breast cancer accepted for filing by the U.S. FDA • Priority Review granted • U.S. FDA grants Priority Review to applications for potential therapies that, if approved, would be significant improvements in the safety or effectiveness of the treatment, diagnosis, or 1 prevention of serious conditions when compared to standard applications • PDUFA target action date of February 28, 2021 • FDA indicated it is currently not planning to hold an advisory committee meeting • NDA submission based on data from Phase III pivotal study – a randomized, controlled clinical trial designed to compare the safety and efficacy of Oral Paclitaxel monotherapy versus IV Paclitaxel monotherapy for the treatment of metastatic breast cancer 6 1 Source: https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/priority-review September 2020
Study Met Primary ORR Endpoint Statistically Significant Improvement in ORR Compared to IV Paclitaxel (Presented at 2019 SABCS) Confirmed Response Rate Confirmed Response Rate (ITT Population) (Prespecified mITT Population) Δ=14.8% Δ=12.4% p=0.005 p=0.011 40.4% 35.8% 25.6% 23.4% Oral Paclitaxel Group IV Paclitaxel Group Oral Paclitaxel Group IV Paclitaxel Group 7 ITT, intent-to-treat population (N=402); mITT, modified intent-to-treat population (N=360) September 2020Study Met Primary ORR Endpoint Statistically Significant Improvement in ORR Compared to IV Paclitaxel (Presented at 2019 SABCS) Confirmed Response Rate Confirmed Response Rate (ITT Population) (Prespecified mITT Population) Δ=14.8% Δ=12.4% p=0.005 p=0.011 40.4% 35.8% 25.6% 23.4% Oral Paclitaxel Group IV Paclitaxel Group Oral Paclitaxel Group IV Paclitaxel Group 7 ITT, intent-to-treat population (N=402); mITT, modified intent-to-treat population (N=360) September 2020
Overall Survival in Prespecified mITT Population Demonstrated Survival Benefit (Data cut: July 2019) (Presented at 2019 SABCS) OPE IVP HR=0.684 (95% CI: 0.475, 0.985) P=0.0353 Months (Relative to Randomization) Numbers of Subjects at Risk 235 229 218 190 162 130 107 84 66 48 42 31 27 23 18 10 7 4 2 0 OPE 125 121 114 99 85 65 47 40 33 24 17 14 12 11 5 4 3 1 1 IVP Median Censored Patient Discontinued patients Patients ongoing or OS, mITT Estimate, Summary, deaths and survival status being followed up (N=360) mo % (events), % unknown (censored), % (censored), % OPE (n=235) 27.9 68.9 31.1 17.9 51.1 IVP (n=125) 16.9 58.4 41.6 18.4 40.0 8 OPE, Oral Paclitaxel Group; IVP, IV Paclitaxel Group mITT, modified intent-to-treat population (N=360) CI, confidence interval; HR, hazard ratio September 2020 Cumulative Overall SurvivalOverall Survival in Prespecified mITT Population Demonstrated Survival Benefit (Data cut: July 2019) (Presented at 2019 SABCS) OPE IVP HR=0.684 (95% CI: 0.475, 0.985) P=0.0353 Months (Relative to Randomization) Numbers of Subjects at Risk 235 229 218 190 162 130 107 84 66 48 42 31 27 23 18 10 7 4 2 0 OPE 125 121 114 99 85 65 47 40 33 24 17 14 12 11 5 4 3 1 1 IVP Median Censored Patient Discontinued patients Patients ongoing or OS, mITT Estimate, Summary, deaths and survival status being followed up (N=360) mo % (events), % unknown (censored), % (censored), % OPE (n=235) 27.9 68.9 31.1 17.9 51.1 IVP (n=125) 16.9 58.4 41.6 18.4 40.0 8 OPE, Oral Paclitaxel Group; IVP, IV Paclitaxel Group mITT, modified intent-to-treat population (N=360) CI, confidence interval; HR, hazard ratio September 2020 Cumulative Overall Survival
1 Neuropathy-relevant TEAEs (CTCAE Grade ≥2) Safety Population (N=399) (Presented at 2019 SABCS) Numbers of Subjects at Risk OPE 264 263 248 239 225 215 198 185 180 171 158 149 137 128 121 114 103 95 85 78 71 65 60 57 51 IVP 135 129 126 120 117 111 103 96 92 86 70 67 58 52 49 40 34 33 33 29 24 20 20 19 15 9 TEAE, treatment emergent adverse event; OPE, Oral Paclitaxel Group; IVP, IV Paclitaxel Group 1 Neuropathy-relevant TEAEs include burning sensation, dysesthesia, hypoesthesia, hyporeflexia, neuralgia, neuropathy peripheral, neurotoxicity, paresthesia, peripheral motor neuropathy, peripheral sensory neuropathy, and polyneuropathy September 20201 Neuropathy-relevant TEAEs (CTCAE Grade ≥2) Safety Population (N=399) (Presented at 2019 SABCS) Numbers of Subjects at Risk OPE 264 263 248 239 225 215 198 185 180 171 158 149 137 128 121 114 103 95 85 78 71 65 60 57 51 IVP 135 129 126 120 117 111 103 96 92 86 70 67 58 52 49 40 34 33 33 29 24 20 20 19 15 9 TEAE, treatment emergent adverse event; OPE, Oral Paclitaxel Group; IVP, IV Paclitaxel Group 1 Neuropathy-relevant TEAEs include burning sensation, dysesthesia, hypoesthesia, hyporeflexia, neuralgia, neuropathy peripheral, neurotoxicity, paresthesia, peripheral motor neuropathy, peripheral sensory neuropathy, and polyneuropathy September 2020
D E V E L O P M E N T U P D A T E : I n i t i a t i o n o f O r a l P a c l i t a x e l i n t h e I - S P Y 2 T r i a lD E V E L O P M E N T U P D A T E : I n i t i a t i o n o f O r a l P a c l i t a x e l i n t h e I - S P Y 2 T r i a l
I-SPY 2 Trial Overview • I-SPY 2 employs an innovative adaptive randomization trial model, including: Neoadjuvant model Endpoint is pCR Curable population Systemic therapy first I-SPY 2’s early A breast cancer lets you see how surrogate efficacy population where tumors respond to endpoint, pCR, gets standard of care has treatment results faster much room to improve • I-SPY 2 is a Phase 2 trial designed to screen novel agents in the neoadjuvant breast cancer setting • Patients randomized to chemotherapy +/- a novel agent • Endpoint is pathological complete response (pCR) • Graduation: 85% probability of success in a Phase 3 I-SPY 2 TRIAL is sponsored by Quantum Leap Healthcare Collaborative 11 Source: https://www.ispytrials.org/i-spy-platform/i-spy2 September 2020I-SPY 2 Trial Overview • I-SPY 2 employs an innovative adaptive randomization trial model, including: Neoadjuvant model Endpoint is pCR Curable population Systemic therapy first I-SPY 2’s early A breast cancer lets you see how surrogate efficacy population where tumors respond to endpoint, pCR, gets standard of care has treatment results faster much room to improve • I-SPY 2 is a Phase 2 trial designed to screen novel agents in the neoadjuvant breast cancer setting • Patients randomized to chemotherapy +/- a novel agent • Endpoint is pathological complete response (pCR) • Graduation: 85% probability of success in a Phase 3 I-SPY 2 TRIAL is sponsored by Quantum Leap Healthcare Collaborative 11 Source: https://www.ispytrials.org/i-spy-platform/i-spy2 September 2020
I-SPY 2 Trial: Adaptive Overall Study Schema 12 Source: Quantum Leap Healthcare Collaborative September 2020I-SPY 2 Trial: Adaptive Overall Study Schema 12 Source: Quantum Leap Healthcare Collaborative September 2020
I-SPY 2 Principal Investigators from Leading Cancer Centers Institution Site PI Name and Title Institution Site PI Name and Title 13 Source: Quantum Leap Healthcare Collaborative September 2020I-SPY 2 Principal Investigators from Leading Cancer Centers Institution Site PI Name and Title Institution Site PI Name and Title 13 Source: Quantum Leap Healthcare Collaborative September 2020
Surgery I-SPY 2 Launches New Study Arm with Oral Paclitaxel In Combination with GSK’s dostarlimab (PD-1 Antibody) Goal of Study: Evaluate the safety and efficacy of Oral Paclitaxel in combination with dostarlimab +/- carboplatin in the neoadjuvant breast cancer setting Primary Objective: Determine whether this regimen increases the probability of pathologic complete response (pCR) over standard neoadjuvant chemotherapy alone in specific biomarker signatures Targeting stage 2/3 HER2+ and HER2- breast cancer patients Experimental arm Oral Paclitaxel + AC Dostarlimab * Experimental arm Oral Paclitaxel + Dostarlimab + AC Carboplatin * Control arm IV Paclitaxel * AC AC = doxorubicin / * HER2+ patients may also cyclophosphamide receive trastuzumab chemotherapy 14 September 2020Surgery I-SPY 2 Launches New Study Arm with Oral Paclitaxel In Combination with GSK’s dostarlimab (PD-1 Antibody) Goal of Study: Evaluate the safety and efficacy of Oral Paclitaxel in combination with dostarlimab +/- carboplatin in the neoadjuvant breast cancer setting Primary Objective: Determine whether this regimen increases the probability of pathologic complete response (pCR) over standard neoadjuvant chemotherapy alone in specific biomarker signatures Targeting stage 2/3 HER2+ and HER2- breast cancer patients Experimental arm Oral Paclitaxel + AC Dostarlimab * Experimental arm Oral Paclitaxel + Dostarlimab + AC Carboplatin * Control arm IV Paclitaxel * AC AC = doxorubicin / * HER2+ patients may also cyclophosphamide receive trastuzumab chemotherapy 14 September 2020
Ongoing Phase II Study of Oral Paclitaxel in Angiosarcoma Interim Data Presented at ASCO20 Virtual Scientific Program 1 Early Onset of Response – CR at Week 13 Baseline Week 1 Week 2 2 Early Onset of Response – CR at Week 6 15 ASCO20 Poster Presentation ”A Phase II Study of Oral Paclitaxel with Encequidar in the Treatment of Unresectable Cutaneous Angiosarcoma” 1 Scalp Angiosarcoma, male, age 93 2 Breast Angiosarcoma, female, age 69 September 2020Ongoing Phase II Study of Oral Paclitaxel in Angiosarcoma Interim Data Presented at ASCO20 Virtual Scientific Program 1 Early Onset of Response – CR at Week 13 Baseline Week 1 Week 2 2 Early Onset of Response – CR at Week 6 15 ASCO20 Poster Presentation ”A Phase II Study of Oral Paclitaxel with Encequidar in the Treatment of Unresectable Cutaneous Angiosarcoma” 1 Scalp Angiosarcoma, male, age 93 2 Breast Angiosarcoma, female, age 69 September 2020
I-SPY 2 Agent Timeline 16 Source: Quantum Leap Healthcare Collaborative September 2020I-SPY 2 Agent Timeline 16 Source: Quantum Leap Healthcare Collaborative September 2020
C O M M E R C I A L S T R A T E G YC O M M E R C I A L S T R A T E G Y
Establishing Athenex’s Leadership in Oncology Positioning Oral Paclitaxel to become the preferred chemotherapy in metastatic breast cancer (MBC)* • Strong Phase III clinical data, comparing to IV Paclitaxel, in MBC Oral Paclitaxel potential label expansion opportunities to multiple indications* • IV Paclitaxel is a foundational chemotherapy • Exploring additional indications, monotherapy and in combination Seeking to revolutionize other IV chemotherapies into oral agents • Orascovery platform: converting other commonly used IV chemotherapy agents into oral • Encequidar, a specific and potent P-gp pump inhibitor, is designed to enable oral administration of chemotherapy agents Broad oncology-focused pipeline 18 * If approved for MBC September 2020Establishing Athenex’s Leadership in Oncology Positioning Oral Paclitaxel to become the preferred chemotherapy in metastatic breast cancer (MBC)* • Strong Phase III clinical data, comparing to IV Paclitaxel, in MBC Oral Paclitaxel potential label expansion opportunities to multiple indications* • IV Paclitaxel is a foundational chemotherapy • Exploring additional indications, monotherapy and in combination Seeking to revolutionize other IV chemotherapies into oral agents • Orascovery platform: converting other commonly used IV chemotherapy agents into oral • Encequidar, a specific and potent P-gp pump inhibitor, is designed to enable oral administration of chemotherapy agents Broad oncology-focused pipeline 18 * If approved for MBC September 2020
Commercial Strategy for Oral Paclitaxel in MBC* Executing a Potential U.S. Launch around Critical Success Factors Emphasize strong clinical data Optimize messaging Increased demand for oral therapies Build company and product awareness Build awareness Highlight strong clinical results Enhance U.S. doctor and patient experience Develop patient engagement services Ensure strong patient support & access Remove economic barriers Elevate importance of Increase awareness and understanding of the problem of neuropathy CIPN Rapid adoption into priority MBC patient segments Establish success in MBC Establish thought leader endorsement 19 * If approved September 2020Commercial Strategy for Oral Paclitaxel in MBC* Executing a Potential U.S. Launch around Critical Success Factors Emphasize strong clinical data Optimize messaging Increased demand for oral therapies Build company and product awareness Build awareness Highlight strong clinical results Enhance U.S. doctor and patient experience Develop patient engagement services Ensure strong patient support & access Remove economic barriers Elevate importance of Increase awareness and understanding of the problem of neuropathy CIPN Rapid adoption into priority MBC patient segments Establish success in MBC Establish thought leader endorsement 19 * If approved September 2020
Commercial Preparations on Track MARKETING SALES MEDICAL AFFAIRS MARKET ACCESS Scientific Trade and distribution “Facing MBC Together” Account targeting communication platform strategy defined campaign launched complete established Data infrastructure being Payer value proposition Brand positioning and Key data generation built out along with research in process customer segmentation and publication plans in customer relationship established process management platform Pricing and contracting research complete Go-to-market tactical Health economics Target team of 50-55 plan identified studies initiated sales reps Patient support strategies in HCP unbranded MSL team fully staffed • Hiring on schedule; development campaign launched to and engaging with 25 territory reps elevate CIPN thought leaders upon approval to Director of Payor team cover 70% of the hired; payor account Oncology nurse highest prescribers team hiring in progress educator team hired 20 September 2020Commercial Preparations on Track MARKETING SALES MEDICAL AFFAIRS MARKET ACCESS Scientific Trade and distribution “Facing MBC Together” Account targeting communication platform strategy defined campaign launched complete established Data infrastructure being Payer value proposition Brand positioning and Key data generation built out along with research in process customer segmentation and publication plans in customer relationship established process management platform Pricing and contracting research complete Go-to-market tactical Health economics Target team of 50-55 plan identified studies initiated sales reps Patient support strategies in HCP unbranded MSL team fully staffed • Hiring on schedule; development campaign launched to and engaging with 25 territory reps elevate CIPN thought leaders upon approval to Director of Payor team cover 70% of the hired; payor account Oncology nurse highest prescribers team hiring in progress educator team hired 20 September 2020
Market Opportunity for Oral Paclitaxel in MBC in the U.S. Metastatic Breast Cancer HER2+ HR+/HER2- TNBC Unknown 1 1 1 1 ~14% ~68% ~10% ~8% Endocrine therapy Oral Paclitaxel and Common regimens 1L +/- CDK 4 & 6 inhibitor Encequidar • Herceptin in combination with paclitaxel • Herceptin Oral Paclitaxel and 2L monotherapy Encequidar • Kadcyla monotherapy • Perjeta in combination with Oral Paclitaxel and Herceptin and 3L Encequidar docetaxel 2 Addressable Market of ~70,000 in MBC 1 National Cancer Institute (SEER 2013-2017) 21 2 Estimated target patients that would be eligible for chemotherapy (various sources, Breast Cancer, United States, 2019). Forecast figures and/or estimates are not guarantees of future performance and involve risks and uncertainties. Actual results might differ materially from September 2020 the forecast figures and/or estimatesMarket Opportunity for Oral Paclitaxel in MBC in the U.S. Metastatic Breast Cancer HER2+ HR+/HER2- TNBC Unknown 1 1 1 1 ~14% ~68% ~10% ~8% Endocrine therapy Oral Paclitaxel and Common regimens 1L +/- CDK 4 & 6 inhibitor Encequidar • Herceptin in combination with paclitaxel • Herceptin Oral Paclitaxel and 2L monotherapy Encequidar • Kadcyla monotherapy • Perjeta in combination with Oral Paclitaxel and Herceptin and 3L Encequidar docetaxel 2 Addressable Market of ~70,000 in MBC 1 National Cancer Institute (SEER 2013-2017) 21 2 Estimated target patients that would be eligible for chemotherapy (various sources, Breast Cancer, United States, 2019). Forecast figures and/or estimates are not guarantees of future performance and involve risks and uncertainties. Actual results might differ materially from September 2020 the forecast figures and/or estimates
L A B E L E X P A N S I O N S T R A T E G I E SL A B E L E X P A N S I O N S T R A T E G I E S
Label Expansion Strategies Pursue opportunities Pursue emerging where paclitaxel is, and combination opportunities will continue to be, the standard of care Time to Regulatory Commercial approval pathway opportunity - Probability of Unmet success medical need Financial Competitive Partner investment landscape participation and ROI 22 September 2020Label Expansion Strategies Pursue opportunities Pursue emerging where paclitaxel is, and combination opportunities will continue to be, the standard of care Time to Regulatory Commercial approval pathway opportunity - Probability of Unmet success medical need Financial Competitive Partner investment landscape participation and ROI 22 September 2020
Potential Areas of Interest Pursue opportunities Pursue emerging where paclitaxel is, and combination opportunities will continue to be, the standard of care Expanding into indications where Combining with immunotherapies Paclitaxel is SOC Early stage breast cancer Lung cancer Ovarian cancer Gastroesophageal (GE) cancer Lung cancer Genitourinary (GU) cancer Gastric cancer TNBC Indications with ongoing studies 24 September 2020Potential Areas of Interest Pursue opportunities Pursue emerging where paclitaxel is, and combination opportunities will continue to be, the standard of care Expanding into indications where Combining with immunotherapies Paclitaxel is SOC Early stage breast cancer Lung cancer Ovarian cancer Gastroesophageal (GE) cancer Lung cancer Genitourinary (GU) cancer Gastric cancer TNBC Indications with ongoing studies 24 September 2020
Opportunity to Expand Oral Paclitaxel’s Addressable Market Potential Addressable US Patients: 545,000 > 545,000 (US Incidence) 25,000 42,000 18,000 35,000 149,000 276,000 Early Stage BC Metastatic 70,000 Current Total Breast Metastatic Metastatic Metastatic Metastatic Head Metastatic 1 Addressable Cancer NSCLC Gastric & Ovarian Cancer & Neck Cancer Bladder Cancer Market in MBC Esophageal Cancer 25 Source: New cases in 2020 estimated based on SEER by National Cancer Institute Note: The graph is for illustrative purpose only. It may not reflect the actual scale and the selected diseases do not represent our comprehensive list of targeted indications September 2020 1 Including laryngeal, oral cavity and pharyngeal cancersOpportunity to Expand Oral Paclitaxel’s Addressable Market Potential Addressable US Patients: 545,000 > 545,000 (US Incidence) 25,000 42,000 18,000 35,000 149,000 276,000 Early Stage BC Metastatic 70,000 Current Total Breast Metastatic Metastatic Metastatic Metastatic Head Metastatic 1 Addressable Cancer NSCLC Gastric & Ovarian Cancer & Neck Cancer Bladder Cancer Market in MBC Esophageal Cancer 25 Source: New cases in 2020 estimated based on SEER by National Cancer Institute Note: The graph is for illustrative purpose only. It may not reflect the actual scale and the selected diseases do not represent our comprehensive list of targeted indications September 2020 1 Including laryngeal, oral cavity and pharyngeal cancers
K E Y T A K E A W A Y SK E Y T A K E A W A Y S
Oral Paclitaxel is the first step in establishing Athenex’s leadership in oral chemotherapy and oncology Advance development of the broader Orascovery pipeline Oral Paclitaxel provides further validation of the technology platform Expand usage of Oral Paclitaxel in other cancer Establish Oral Oral docetaxel and encequidar types Paclitaxel as • Phase II study in planning SOC in breast cancer Opportunities where Oral irinotecan and encequidar paclitaxel is currently • Phase II study in planning used and in emerging Metastatic breast combinations, e.g.: cancer • Gastric cancer Oral eribulin and encequidar Early stage breast • Lung cancer • Phase I study ongoing cancer (I-SPY 2) • Ovarian cancer • TNBC 27 September 2020Oral Paclitaxel is the first step in establishing Athenex’s leadership in oral chemotherapy and oncology Advance development of the broader Orascovery pipeline Oral Paclitaxel provides further validation of the technology platform Expand usage of Oral Paclitaxel in other cancer Establish Oral Oral docetaxel and encequidar types Paclitaxel as • Phase II study in planning SOC in breast cancer Opportunities where Oral irinotecan and encequidar paclitaxel is currently • Phase II study in planning used and in emerging Metastatic breast combinations, e.g.: cancer • Gastric cancer Oral eribulin and encequidar Early stage breast • Lung cancer • Phase I study ongoing cancer (I-SPY 2) • Ovarian cancer • TNBC 27 September 2020
Q&A THANK YOU Our goal is to become a global leader in bringing innovative cancer treatments to the market and improving health outcomes NASDAQ:ATNX www.athenex.comQ&A THANK YOU Our goal is to become a global leader in bringing innovative cancer treatments to the market and improving health outcomes NASDAQ:ATNX www.athenex.com